TP53 and head and neck squamous cell carcinoma: Compared with HPV- HNSCC, HPV+ HNSCC has been shown to exhibit a better prognosis and sensitivity to radiotherapy and chemotherapy [9], perform a lower mutational burden, expressed a wild TP53 [10,11], have more tumor-infiltrating lymphocytes [12] as well as the less hypoxic [13], however, why HPV+ HNSCC performs better prognosis and the sensitivity of radiotherapy and chemotherapy still remains unclear.